{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.414","value":"204"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"CL is a quantitative measure of the rate at which a drug substance is removed from the body. The following allometric scaling equation was used for the estimation of CL in children:\n\nCL= qCL X (BSA/1.9) 0.92 X 1.31\\*ADA\n\nwhere qCL is a typical value of clearance in millilitres per day (mL/day) for a typical participant (i.e., Body Surface Area (BSA) of 1.9 m\\^2 and absence of anti-rituximab antibodies (ADA)) and is equal to 258 mL/day; BSA is in m\\^2 and ADA is 1 when anti-rituximab antibodies are present (0 otherwise). The allometric scaling factor was 0.92. CL was calculated in millilitres per day (mL/day).","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received rituximab as an intravenous (IV) infusion of 375 milligrams per meter squared (mg/m\\^2) once a week on Days 1, 8, 15 and 22 during the Remission Induction Phase (Day 1 (baseline) to Month 6) and were followed for a minimum of 18 months (maximum 4.5yrs) during the Follow-up Phase until the Common-closeout (CCO))","id":"OG000","title":"Rituximab (Experimental)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis population included all participants in the safety population who provided at least one evaluable PK sample.","reportingStatus":"POSTED","timeFrame":"From Day 1 to Day 180","title":"Pharmacokinetics: Rituximab Clearance (CL)","type":"PRIMARY","unitOfMeasure":"mL/day"}